Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Date:4/22/2008

FDA agrees to first SPA for an oncolytic product

WOBURN, Mass., April 22 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX(GM-CSF) in previously treated patients with metastatic melanoma. The agreement was made under the Special Protocol Assessment (SPA) procedure.

BioVex is currently concluding a 50-patient Phase II trial for OncoVEX(GM-CSF) as stand alone therapy in patients with unresectable Stage IIIc and Stage IV metastatic melanoma. The trial was designed to measure overall objective response, which is defined as a complete response (CR), where disease is completely eliminated, or partial response (PR), where there is a >30% reduction in disease burden. Interim results from the study demonstrated a highly encouraging rate of durable objective response with multiple patients with metastatic disease at enrollment having been declared disease free following therapy. The full study has been accepted for oral presentation at ASCO on June 1st where the results will be presented.

The Phase III study design agreed with the FDA follows directly from the study design successfully employed in Phase II. The Phase III study will also enroll previously treated patients with unresectable stage IIIc and stage IV disease using OncoVEX(GM-CSF) as monotherapy. The primary efficacy endpoint will also be response rate-based; the primary objective being to demonstrate a statistically significant increase in the rate of objective responses maintained for six months or more, in comparison to control therapy (subcutaneously administered(GM-CSF). The study is intended to enroll 360 evaluable patients randomized such that 240 patients receive OncoVEX(GM-CSF) and 120 patients receive contro
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Provides Further Comments on the Pivotal Phase III Trials
2. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
3. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
6. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
7. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015  Intec Pharma Ltd. (the ... company focused on developing drugs based on its proprietary ... its initial public offering in the United ... at a price to the public of $6.00 per ... the ordinary shares are being offered by the Company.  ...
(Date:8/4/2015)... NEW YORK , August 4, 2015 /PRNewswire/ ... new research report with market overview, trends, DRO ... analysis, recent developments, competitive scenario and top competitor ... of Abuse Testing Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) , Explore full reports ...
(Date:8/4/2015)... Tenn., Aug. 4, 2015 Second Quarter ... 30.1% over second quarter of 2014 , Net earnings ... million; $51.2 million after adjustments , Diluted net earnings ... Adjusted EBITDA increased 15.2% to $99.4 million ... to a range of 24.0% to 26.0%; Adjusted EBITDA margin ...
Breaking Medicine Technology:Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30
... Conference on Avian,Influenza at France's Pasteur Institute, PARIS, ... of,Novavax Inc.'s pandemic influenza vaccine provided protection,against a ... data presented here today at the Second International,Conference ... show that two 0.6 microgram doses of Novavax's,virus-like ...
... of Rare but Devastating,Condition , LONDON, June 1, ... of Leicester and have today (Friday June 1),announced ... rare but,devastating medical condition that can affect children ... clinicians and scientists from the two,universities have already ...
Cached Medicine Technology:Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 2Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 3Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 2World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 3World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 5
(Date:8/5/2015)... ... August 05, 2015 , ... What language does a body ... unique “dictionary” of American idioms and other expressions that contain the name of a ... entertaining. This book contains about 2,000 such idioms, words, and expressions, for example, “back ...
(Date:8/5/2015)... ... August 05, 2015 , ... " Wildflower Seed & Tool Company ” ... look small, medium, and large businesses making an impact in their industry. Susan Bridges, ... with viewers how their gardening tools are specifically designed for women. , With overweight ...
(Date:8/5/2015)... ... August 05, 2015 , ... ... funding, as well as awareness, education and support in order to reduce the ... Foundation proudly announces this year it has awarded the most funding in ...
(Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... ... a Texas-based corporation, Crestwood Midstream, to store liquid propane gas (LPG) next to ... powerful healthcare workers union, unanimously passed a resolution that strongly opposes that permit. ...
(Date:8/4/2015)... , ... August 04, 2015 , ... NOVA Pride ... of whom or how they love or identify, to join them in paving “The ... Bull Run Special Events Center on Saturday, October 3, 2015, from 12-9pm. In order ...
Breaking Medicine News(10 mins):Health News:Harvard Medical Professor Dr. Per-Olof Hasselgren Pens Unique Book Using Body Part Idioms 2Health News:Wildflower Seed & Tool Company Design Gardening Tools Specifically for Women 2Health News:Brain Aneurysm Foundation Awards Largest Amount of Research Funding at 9th Annual Brain Aneurysm Foundation Research Grant Awards Symposium Sept 10th in Houston, Texas 2Health News:Brain Aneurysm Foundation Awards Largest Amount of Research Funding at 9th Annual Brain Aneurysm Foundation Research Grant Awards Symposium Sept 10th in Houston, Texas 3Health News:Brain Aneurysm Foundation Awards Largest Amount of Research Funding at 9th Annual Brain Aneurysm Foundation Research Grant Awards Symposium Sept 10th in Houston, Texas 4Health News:Opposition Mounting to Permit Liquid Propane Gas Storage Next to New York’s Seneca Lake 2Health News:Opposition Mounting to Permit Liquid Propane Gas Storage Next to New York’s Seneca Lake 3Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 2Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 3Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 4
... medical condition, has been and remains under-identified. While it ... people who are at high risk for CKD are ... risk for potentially undiagnosed CKD, a team of public ... and the University of North Carolina (UNC) at Chapel ...
... carry a pronounced risk of suffering weak bones due ... Therefore, physicians need to be vigilant to spot bone ... the report the mix of sedentary behaviors and side ... in suppression of bone growth and mineralization. This makes ...
... turn with the involvement of social services in the case of ... above three times the average for his age. ,The ... does not undergo a sea change. He holds a record of ... ,Connor’s mother and grandmother are expected to attend a ...
... day for 10 years, a seemingly heart-healthy 53-year-old woman ... or family history of hypertension or hyperthyroidism. She did ... any abnormalities of the heart as best doctors and ... palpitations and dizziness nearly to the point of fainting. ...
... the most common treatments for prostate cancer - may increase ... age 65, according to a new study. ,The ... registry of men with prostate cancer. Although the findings need ... that oncologists should weigh the benefits of androgen deprivation therapy, ...
... with a drug used previously in the treatment of ... rats// to human subjects. ,The researchers ... administered daily to the rats which were bred to ... improvement in learning abilities. ,Down's syndrome is ...
Cached Medicine News:Health News:Simple Model to Predict Chronic Kidney Disease 2Health News:Simple Model to Predict Chronic Kidney Disease 3Health News:Bone Fragility, a Risk for Children With Cancer 2Health News:Grossly Overweight Boy Likely to Be Sent into Care 2Health News:Irregular Heartbeat Linked to Genetic Mutation 2Health News:Prostate Cancer Therapy may Increase Risk of Death in Older Patients 2Health News:Discredited Drug may Be Used to Aid Mental Development in Down’s Syndrome Patient 2
... sample processing consists of a clear glass ... a chemical-resistant polypropylene lid, and a set ... The manifold is designed for consistent processing ... simultaneously. Loading, washing, and elution steps can ...
For processing spin columns on QIAvac 24 or QIAvac 6S;...
For processing mini spin columns on QIAvac 24;...
DNA/RNA preparation in 96-well format...
Medicine Products: